Romero P, Pannetier C, Herman J, Jongeneel C V, Cerottini J C, Coulie P G
Ludwig Institute for Cancer Research, Lausanne Branch, University of Lausanne, Epalinges, Switzerland.
J Exp Med. 1995 Oct 1;182(4):1019-28. doi: 10.1084/jem.182.4.1019.
Peptide MAGE-1.A1 is a nonamer derived from protein MAGE-1 that can associate with the HLA-A1 molecule. It was shown previously to be recognized by an antitumor cytolytic T lymphocyte (CTL) clone derived from the blood of melanoma patient MZ2. We derived two other anti-MAGE-1.A1 CTL clones from different blood samples of the same patient and compared the fine specificity of recognition of the three CTL by testing them on variant MAGE-1.A1 peptides incorporating different amino acid substitutions. The epitopes recognized by the CTL proved to be different. While modifications of residues at positions 5, 6, or 7 in the antigenic peptide affected recognition by the three CTL, each of the modifications of residues at positions 1, 4, or 8 affected recognition by one CTL only. The sequences of both the alpha and beta chains of the T cell antigen receptor of the three CTL were completely different. The results indicate a long-lasting diversity in terms of fine specificity and of T cell antigen receptor structure in the repertoire of antitumor CTL derived from the blood of a melanoma patient and directed against a defined tumor antigen.
肽MAGE-1.A1是一种源自蛋白质MAGE-1的九聚体,可与HLA-A1分子结合。先前已证明它能被源自黑色素瘤患者MZ2血液的抗肿瘤细胞溶解T淋巴细胞(CTL)克隆识别。我们从同一患者的不同血液样本中获得了另外两个抗MAGE-1.A1 CTL克隆,并通过在包含不同氨基酸取代的变体MAGE-1.A1肽上测试这三个CTL,比较了它们识别的精细特异性。结果证明CTL识别的表位是不同的。虽然抗原肽中第5、6或7位残基的修饰会影响这三个CTL的识别,但第1、4或8位残基的每一种修饰仅影响一个CTL的识别。这三个CTL的T细胞抗原受体的α链和β链序列完全不同。结果表明,源自黑色素瘤患者血液并针对特定肿瘤抗原的抗肿瘤CTL库在精细特异性和T细胞抗原受体结构方面存在长期的多样性。